Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments

Neurological Sciences

Volumn 26, Issue SUPPL. 4, 2005, Pages

  Malucchi, S ^a   Capobianco, M ^a   Marnetto, F ^a   Caldano, M ^a   Sala, A ^a   Bertolotto, A ^a  

^a SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Bioavailability; IFN ; mRNA MxA; NAbs

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MESSENGER RNA; METHYLPREDNISOLONE; MITOXANTRONE; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PROTEIN EXPRESSION; RELAPSE; REMISSION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; BIOLOGICAL AVAILABILITY; GTP-BINDING PROTEINS; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROGNOSIS; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 30644457182     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-005-0517-3     Document Type: Article

References (10)

1. Deisenhammer F, Reindl M, Harvey J et al (1999) Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 62:1239-1243
2. Vallittu AM, Halminen M, Peltoniemi J and the Finnish Beta-Interferon Study Group (2002) Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients. Neurology 58:1786-1790
3. Bertolotto A, Gilli F, Sala A et al (2001) Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 256:141-152
4. Bertolotto A, Gilli F, Sala A et al (2003) Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 60:634-639
5. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta 1-b: Experience during the first three years. Neurology 47:889-894
6. The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: Long-term efficacy of interferon-β-1a relapsing MS. Neurology 56:1628-1636
7. Sorensen PS, Ross C, Clemmesen KM et al (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184-1191
8. Malucchi S, Sala A, Gilli F et al (2004) Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis. Neurology 62:2031-2037
9. Gilli F, Marnetto F, Stefanuto G et al (2004) Comparison of three PCR assay for the evaluation of interferon-beta biological activity in patients with multiple sclerosis. Mol Diagn 8:185-194
10. Gilli F, Marnetto F, Caldano M et al (2005) Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol 158:195-203